A61K 38/556
Angiotensin converting enzyme inhibitors
Official title: {Angiotensin converting enzyme inhibitors}
A61K38/556 (Angiotensin converting enzyme inhibitors) appears on 152 US grants and 138 published applications in this corpus.
Search patents in A61K- Granted patents
- 152
- Published applications
- 138
- Assignees
- 129
- Inventors
- 377
- Latest grant
- 1 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1984 | 1 | 0 |
| 1985 | 1 | 0 |
| 1986 | 0 | 0 |
| 1987 | 1 | 0 |
| 1988 | 1 | 0 |
| 1989 | 1 | 0 |
| 1990 | 4 | 0 |
| 1991 | 3 | 0 |
| 1992 | 5 | 0 |
| 1993 | 9 | 0 |
| 1994 | 5 | 0 |
| 1995 | 7 | 0 |
| 1996 | 7 | 0 |
| 1997 | 7 | 0 |
| 1998 | 7 | 0 |
| 1999 | 8 | 0 |
| 2000 | 6 | 0 |
| 2001 | 12 | 2 |
| 2002 | 8 | 5 |
| 2003 | 7 | 21 |
| 2004 | 4 | 14 |
| 2005 | 3 | 12 |
| 2006 | 4 | 7 |
| 2007 | 1 | 6 |
| 2008 | 2 | 12 |
| 2009 | 0 | 8 |
| 2010 | 10 | 5 |
| 2011 | 4 | 5 |
| 2012 | 3 | 4 |
| 2013 | 0 | 3 |
| 2014 | 4 | 6 |
| 2015 | 0 | 4 |
| 2016 | 3 | 3 |
| 2017 | 2 | 3 |
| 2018 | 4 | 1 |
| 2019 | 1 | 5 |
| 2020 | 1 | 1 |
| 2021 | 1 | 4 |
| 2022 | 0 | 2 |
| 2023 | 4 | 2 |
| 2024 | 0 | 2 |
| 2025 | 0 | 0 |
| 2026 | 1 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Method of treating drug resistant hypertension and heart failure with preserved ejection fraction by combined drug treatment with baropacing and beta blockers1 Sep 2026US 12,722,014 B2BaroPace, Inc.
- Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors19 Dec 2023US 11,845,989 B2Regeneron Pharmaceuticals, Inc.
- Compositions and methods for treating COVID-1922 Aug 2023US 11,732,264 B2Vast Sea Biotechnology, Inc.
- Micronutrient combination to reduce blood pressure6 Jun 2023US 11,666,643 B1
- Micronutrient combination to reduce blood pressure7 Feb 2023US 11,571,468 B2
- Composition for preventing heart diseases caused by pulmonary hypertension and treating heart, and functional formulation comprising same23 Apr 2026US 2026/0108532 A1Careside, Inc.
- Therapeutic uses of dulaglutide20 Jun 2024US 2024/0197835 A1Eli Lilly and Company
- Method of treating drug resistant hypertension and heart failure with preserved ejection fraction by combined drug treatment with baropacing and beta blockers18 Jan 2024US 2024/0017077 A1BaroPace, Inc.
- Pharmaceutical combination comprising a brain aminopeptidase a inhibitor, a diuretic and a blocker of the systemic renin-angiotensin system27 Jul 2023US 2023/0233492 A1Centre National De La Recherche Scientifique
- Opthalmic Compositions for Treating Coronaviruses13 Apr 2023US 2023/0111350 A1
Most cited
By later US patents
- Localized use of nitric oxide-adducts to prevent internal tissue damage146US 6,087,479 ANitroMed, Inc. · 2000
- Stabilized compositions123US 4,743,450 AWarner-Lambert Company · 1988
- Therapy delayed93US 5,190,765 AAlza Corporation · 1993
- Controlling nitrogen oxide concentrations to modulate skeletal muscle contraction82US 5,545,614 ADuke Univ. · 1996
- Therapy delayed77US 5,252,338 AAlza Corporation · 1993